Total Payments
$30,721
2024 Payments
$2,009
Companies
88
Transactions
892
Medicare Patients
13,433
Medicare Billing
$2.4M
Payment Breakdown by Category
Food & Beverage$17,251 (56.2%)
Research$13,205 (43.0%)
Education$265.08 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $17,251 | 879 | 56.2% |
| Unspecified | $13,205 | 5 | 43.0% |
| Education | $265.08 | 8 | 0.9% |
Payments by Type
General
$17,516
887 transactions
Research
$13,205
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $11,668 | 86 | $0 (2024) |
| Eli Lilly and Company | $2,820 | 2 | $0 (2021) |
| Merck Sharp & Dohme LLC | $1,717 | 80 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,550 | 88 | $0 (2024) |
| Celgene Corporation | $910.27 | 32 | $0 (2024) |
| Genentech USA, Inc. | $834.29 | 52 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $829.50 | 44 | $0 (2024) |
| Janssen Biotech, Inc. | $802.59 | 45 | $0 (2024) |
| PFIZER INC. | $798.66 | 52 | $0 (2024) |
| Amgen Inc. | $689.98 | 35 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,009 | 95 | Novartis Pharmaceuticals Corporation ($166.50) |
| 2023 | $2,491 | 115 | Novartis Pharmaceuticals Corporation ($222.61) |
| 2022 | $2,555 | 126 | Novartis Pharmaceuticals Corporation ($230.53) |
| 2021 | $4,690 | 107 | Eli Lilly and Company ($2,576) |
| 2020 | $1,733 | 89 | AstraZeneca Pharmaceuticals LP ($164.14) |
| 2019 | $12,561 | 119 | E.R. Squibb & Sons, L.L.C. ($10,521) |
| 2018 | $2,422 | 113 | Merck Sharp & Dohme Corporation ($366.80) |
| 2017 | $2,261 | 128 | Novartis Pharmaceuticals Corporation ($367.79) |
All Payment Transactions
892 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: HORMONE THERAPY | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: Immunology | ||||||
| 12/13/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/12/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $23.23 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/06/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $32.37 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $25.50 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/26/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Oncology | ||||||
| 11/25/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $27.79 | General |
| 11/15/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: BioOncology | ||||||
| 11/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.83 | General |
| Category: Immunology | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $24.83 | General |
| Category: Oncology | ||||||
| 10/25/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $20.93 | General |
| 10/17/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/15/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: HORMONE THERAPY | ||||||
| 10/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.32 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.84 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Nivo Dose Frequency Optimization Lung Trial | E.R. Squibb & Sons, L.L.C. | $6,810 | 1 |
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $2,576 | 1 |
| A ph IIIB IV Safety Trial of Nivo Combined with Ipili w and wout prior nivo in Subjects with Advanced or Metastatic Renal Cell Carcinoma | E.R. Squibb & Sons, L.L.C. | $2,536 | 1 |
| Nivo RCC Safety Trial | E.R. Squibb & Sons, L.L.C. | $1,039 | 1 |
| A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION | Eli Lilly and Company | $244.45 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 681 | 1,184 | $312,643 | $108,197 |
| 2022 | 60 | 3,839 | 83,494 | $1.6M | $572,444 |
| 2021 | 65 | 4,576 | 154,248 | $2.5M | $868,020 |
| 2020 | 66 | 4,337 | 135,439 | $2.7M | $889,096 |
Total Patients
13,433
Total Services
374,365
Medicare Billing
$2.4M
Procedure Codes
202
All Medicare Procedures & Services
202 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 186 | 363 | $89,661 | $31,874 | 35.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 92 | 219 | $79,716 | $28,470 | 35.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 150 | 177 | $29,028 | $10,300 | 35.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 113 | $25,651 | $10,182 | 39.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 83 | 83 | $33,532 | $9,184 | 27.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 46 | 106 | $16,960 | $6,348 | 37.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $13,905 | $4,221 | 30.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 28 | 30 | $13,440 | $3,941 | 29.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 22 | 22 | $7,062 | $2,165 | 30.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 31 | $3,038 | $1,163 | 38.3% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 12 | 13 | $650.00 | $349.91 | 53.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 44 | 10,621 | $303,056 | $179,260 | 59.2% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2022 | 31 | 3,500 | $210,000 | $66,644 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 127 | 558 | $101,107 | $51,603 | 51.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 319 | 642 | $74,707 | $38,629 | 51.7% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2022 | 19 | 12,110 | $145,320 | $30,626 | 21.1% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 49 | 178 | $28,480 | $28,331 | 99.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 66 | 272 | $94,112 | $27,101 | 28.8% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2022 | 13 | 73 | $33,580 | $13,433 | 40.0% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2022 | 79 | 86 | $55,900 | $12,850 | 23.0% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2022 | 31 | 18,871 | $58,500 | $11,655 | 19.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 322 | 1,085 | $43,400 | $11,324 | 26.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 342 | 1,251 | $28,773 | $9,603 | 33.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 79 | 129 | $22,575 | $6,236 | 27.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 51 | 51 | $15,429 | $5,844 | 37.9% |
About Dr. Brian Lingerfelt, MD
Dr. Brian Lingerfelt, MD is a Hematology & Oncology healthcare provider based in Charleston, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1942418744.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Lingerfelt, MD has received a total of $30,721 in payments from pharmaceutical and medical device companies, with $2,009 received in 2024. These payments were reported across 892 transactions from 88 companies. The most common payment nature is "Food and Beverage" ($17,251).
As a Medicare-enrolled provider, Lingerfelt has provided services to 13,433 Medicare beneficiaries, totaling 374,365 services with total Medicare billing of $2.4M. Data is available for 4 years (2020–2023), covering 202 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Charleston, SC
- Active Since 05/18/2007
- Last Updated 10/01/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1942418744
Products in Payments
- OPDIVO (Biological) $11,434
- KEYTRUDA (Biological) $1,558
- LIBTAYO (Biological) $475.63
- Revlimid (Drug) $449.01
- KISQALI (Drug) $388.50
- LYNPARZA (Drug) $335.77
- IMBRUVICA (Drug) $319.02
- AFINITOR (Drug) $284.96
- TECENTRIQ (Biological) $262.30
- SARCLISA (Biological) $257.04
- IBRANCE (Drug) $239.46
- JAKAFI (Drug) $215.20
- DARZALEX (Biological) $210.17
- INJECTAFER (Drug) $204.74
- TAGRISSO (Drug) $193.47
- BRUKINSA (Drug) $193.13
- BRAFTOVI (Drug) $186.28
- REBLOZYL (Biological) $184.55
- FOUNDATIONONE (Device) $174.72
- JEVTANA (Drug) $169.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Charleston
Mr. George Geils, M.d, M.D
Hematology & Oncology — Payments: $184,021
Hematology & Oncology $184,021
Mr. David Ellison, M.d, M.D
Hematology & Oncology — Payments: $39,035
Hematology & Oncology $39,035
Dr. Albert Lockhart, Md, MD
Hematology & Oncology — Payments: $36,997
Hematology & Oncology $36,997
Dr. Irl Greenwell, M.d, M.D
Hematology & Oncology — Payments: $30,803
Hematology & Oncology $30,803
Robert Stuart, Md, MD
Hematology & Oncology — Payments: $25,933
Hematology & Oncology $25,933
Dr. George Keogh, M.d, M.D
Hematology & Oncology — Payments: $18,248
Hematology & Oncology $18,248